Lung Cancer
Volume 45 , Pages S121-S124 , August 2004

The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials

References 

  1. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann. Intern. Med. 1982;96:746–755
  2. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax. 1997;52:507–512
  3. Ong St, Vogelzang NJ. Chemotherapy in malignant pleura mesothelioma: a review. J. Clin. Oncol. 1996;14:1007–1017
  4. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;113:66S–73S
  5. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleura mesothelioma: A disease unaffected by current therapeutic maneuvers. J. Clin. Oncol. 1988;6:527–535
  6. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al.  Multitrargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999;17:1194
  7. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, et al.  Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer. 2000;88:1807–1833
  8. Miles DW, Smith IE, Coleman RE, et al.  A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer. 2001;37:1366–1371
  9. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shin C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999 (Suppl 6);26:68–73.
  10. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. 1999;26(Suppl 6):42–47
  11. Moran RG. Roles of folypoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 1999;26(Suppl 6):24–32
  12. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J, Schultz RM. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26(2 Suppl 6):55–62.
  13. Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, et al.  Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 2000;6(3):1016–1023
  14. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999;59(15):3671–3676
  15. McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, et al.  A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 1998;4:605–610
  16. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckhardt SG, et al.  Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Cin. Oncol. 1995;13:2842–2850
  17. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al.  A phase I evaluation of multitargeted antifolate (MTA, LY231514), administerd every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 1999;44:372–380
  18. Fossella FV, Gatzemeier U. Phase I trails of pemetrexed. Semin. Oncol. 2002;29(Suppl. 5):8–16
  19. Thödtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR, et al.  Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin. J. Clin. Oncol. 1999;17:3009–3016
  20. Calvert AH, Hughes AN, Calvert PM. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer. 2000;29(Suppl. 2):73–74
  21. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as fornt-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 2003;21:1556–1561
  22. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al.  Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002;1:545–552
  23. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003;21:2636–2644

PII: S0169-5002(04)00182-5

doi: 10.1016/j.lungcan.2004.04.021

Lung Cancer
Volume 45 , Pages S121-S124 , August 2004

Article Tools